Form 4: Amneal Pharmaceuticals Director John Kiely Reports Stock Transactions

Director John Kiely reports acquisition of Amneal Pharmaceuticals Class A Common Stock through vesting of restricted stock units.

Summary

• On May 5, 2025, Director John Kiely acquired 40,258 shares of Amneal Pharmaceuticals Class A Common Stock upon the vesting of restricted stock units.
• Following this transaction, Kiely directly owns 307,433 shares of Class A Common Stock.
• Kiely also acquired 34,819 restricted stock units on May 6, 2025, which will vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.
• After this transaction, Kiely directly owns 34,819 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry and other publicly traded companies.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Form 4, Beneficial Ownership, Director, Stock Transaction, Restricted Stock Units, John Kiely